Arguably, the most clinically relevant basis for the potential of GLP-1 RAs in HF could be their effect on multiple cardiometabolic parameters that play intertwined roles across the HF-related diseases such as diabetes and obesity, which often co-exist. This evidence concerns the gene GCG and obesity disorder.